Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
Today, heart failure is one of the leading causes of death and disability in most developed and developing countries. By 2030, more than 23.3 million people are projected to die of cardiovascular diseases each...
Source: Health Economics Review - Category: Health Management Authors: Ramin Ravangard, Farideh Sadat Jalali, Marjan Hajahmadi and Abdosaleh Jafari Tags: Research Source Type: research
More News: Cardiology | Cardiovascular | Diovan | Disability | Economics | Enalapril | Health Management | Heart | Heart Failure | Iran Health | Middle East Health